Collegium Pharmaceutical (COLL) continues to advance toward becoming the frontrunner in responsible pain management. The company recorded almost 1M portfolio prescriptions in 2019 and increased their full-year net revenue by 6%. This growth is primarily due to the company's Xtampza ER product, which pulled in $105M in net revenue. Collegium continues to secure Xtampza ER formulary wins, which now covers over 35M. What is more, Collegium recently acquired the U.S. rights to the Nucynta franchise. Unfortunately, the market has discounted all its 2019 progress and pulled COLL down in the Coronavirus Crash. I